Ghent University Academic Bibliography

Advanced

Targeted therapy for metastatic renal cell cancer

CAROLINE VERBAEYS UGent, Piet Hoebeke UGent, Simon Van Belle UGent and Sylvie Rottey UGent (2010) ACTA CLINICA BELGICA. 65(2). p.115-121
abstract
Renal cell cancer is a common urological malignancy for which the incidence has doubled over the last three decades. Thirty percent of patients have metastatic disease at the moment of diagnosis. Thirty percent of the remaining surgically treated patients will develop metastases. Before the introduction of targeted therapies the only therapeutic option for these patients was immunotherapy with bad tolerability and poor results. This review discusses these new 'targeted therapies'.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
IMMUNOTHERAPY, SUNITINIB, TEMSIROLIMUS, SORAFENIB, CARCINOMA, DOUBLE-BLIND, INTERFERON-ALPHA, PHASE-III TRIAL, targeted therapy, renal cell cancer, metastasis
journal title
ACTA CLINICA BELGICA
Acta Clin. Belg.
volume
65
issue
2
pages
115 - 121
Web of Science type
Article
Web of Science id
000278507500005
JCR category
MEDICINE, GENERAL & INTERNAL
JCR impact factor
0.532 (2010)
JCR rank
104/151 (2010)
JCR quartile
3 (2010)
ISSN
0001-5512
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
1195855
handle
http://hdl.handle.net/1854/LU-1195855
date created
2011-03-23 17:54:32
date last changed
2016-12-19 15:45:14
@article{1195855,
  abstract     = {Renal cell cancer is a common urological malignancy for which the incidence has doubled over the last three decades. 
Thirty percent of patients have metastatic disease at the moment of diagnosis. Thirty percent of the remaining surgically treated patients will develop metastases. 
Before the introduction of targeted therapies the only therapeutic option for these patients was immunotherapy with bad tolerability and poor results. 
This review discusses these new 'targeted therapies'.},
  author       = {VERBAEYS, CAROLINE and Hoebeke, Piet and Van Belle, Simon and Rottey, Sylvie},
  issn         = {0001-5512},
  journal      = {ACTA CLINICA BELGICA},
  keyword      = {IMMUNOTHERAPY,SUNITINIB,TEMSIROLIMUS,SORAFENIB,CARCINOMA,DOUBLE-BLIND,INTERFERON-ALPHA,PHASE-III TRIAL,targeted therapy,renal cell cancer,metastasis},
  language     = {eng},
  number       = {2},
  pages        = {115--121},
  title        = {Targeted therapy for metastatic renal cell cancer},
  volume       = {65},
  year         = {2010},
}

Chicago
VERBAEYS, CAROLINE, Piet Hoebeke, Simon Van Belle, and Sylvie Rottey. 2010. “Targeted Therapy for Metastatic Renal Cell Cancer.” Acta Clinica Belgica 65 (2): 115–121.
APA
VERBAEYS, CAROLINE, Hoebeke, P., Van Belle, S., & Rottey, S. (2010). Targeted therapy for metastatic renal cell cancer. ACTA CLINICA BELGICA, 65(2), 115–121.
Vancouver
1.
VERBAEYS C, Hoebeke P, Van Belle S, Rottey S. Targeted therapy for metastatic renal cell cancer. ACTA CLINICA BELGICA. 2010;65(2):115–21.
MLA
VERBAEYS, CAROLINE, Piet Hoebeke, Simon Van Belle, et al. “Targeted Therapy for Metastatic Renal Cell Cancer.” ACTA CLINICA BELGICA 65.2 (2010): 115–121. Print.